Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Unicentric, Randomized, Open-label, Cross-over Clinical Trial to Assess the Effect of Dapagliflozin, Spironolactone and Their Combination, When Added to Renin-Angiotensin System Blockade, On Lowering Urine Albumin-to-Creatinine Ratio in Adult Patients With Alport Syndrome

NCT06499948 is registered in ClinicalTrials.gov with Stefan Lujinschi as lead sponsor.

NCT NCT06499948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06499948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Unicentric, Randomized, Open-label, Cross-over Clinical Trial to Assess the Effect of Dapagliflozin, Spironolactone and Their Combination, When Added to Renin-Angiotensin System Blockade, On Lowering Urine Albumin-to-Creatinine Ratio in Adult Patients With Alport Syndrome
Lead sponsor
Stefan Lujinschi
Phase
Phase 4
Overall status
Completed
Start date
February 26, 2024
Completion date
April 30, 2026
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alport nephropathy, alport syndrome, thin basement membrane disease